GLP-1s and Sleep Apnea: What to Know

In December 2024, tirzepatide (Zepbound) became the first drug approved by the FDA to treat moderate-to-severe obstructive sleep apnea in adults with obesity. This is a separate approval from its weight-loss indication. Here's what the evidence shows and what it means if you have sleep apnea.

What is obstructive sleep apnea?

Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing breathing to stop briefly and then restart. These interruptions — called apnea and hypopnea events — can happen many times per hour and disrupt sleep quality significantly without the person always being aware.

Excess weight is a major contributing factor. Fat deposits around the neck and chest narrow the airway and increase the likelihood of collapse during sleep. This is why weight loss has long been associated with improvements in OSA severity — and why a GLP-1 medication's weight-loss effects could plausibly benefit people with sleep apnea.

Severity of OSA is measured by the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep. Moderate OSA is typically defined as 15–30 events per hour; severe OSA is 30 or more per hour.

What did the SURMOUNT-OSA trial show?

The SURMOUNT-OSA trial was the pivotal study that supported the FDA approval of tirzepatide (Zepbound) for obstructive sleep apnea. It enrolled adults with moderate-to-severe OSA and obesity.

The trial showed large reductions in the number of apnea and hypopnea events per hour in participants treated with tirzepatide, compared to placebo. The improvements were clinically meaningful — participants also showed improvements in other sleep-related measures and quality-of-life outcomes.

These results were robust enough to support a separate regulatory approval for the sleep apnea indication — distinct from the weight-management approval already in place for Zepbound.

Is this approval for weight loss or sleep apnea?

The December 2024 FDA approval for tirzepatide (Zepbound) in OSA is a separate indication from its weight-management approval. It specifically applies to adults with moderate-to-severe obstructive sleep apnea and obesity.

This distinction matters for several reasons:

• The approval is for Zepbound (tirzepatide) only — not for Ozempic, Wegovy, or other semaglutide products
• The indication is for a specific combination of conditions — moderate-to-severe OSA in adults with obesity
• Whether insurance or healthcare systems cover the medication for this specific indication varies

If you have sleep apnea and are interested in tirzepatide, speak to your clinician about which indication applies to your situation.

Does weight loss improve sleep apnea generally?

Weight loss — achieved by any means — is associated with improvements in obstructive sleep apnea severity. This is because excess adipose tissue around the neck and chest contributes directly to airway narrowing during sleep. Reducing body weight reduces this mechanical pressure on the airway.

This means that GLP-1 medications prescribed for weight management may also lead to incidental improvements in sleep apnea, even when not specifically indicated for it. However, this is not the same as the specific clinical trial evidence and regulatory approval that supports Zepbound's sleep apnea indication.

If you have sleep apnea and are losing weight on a GLP-1, discuss with your sleep specialist whether your CPAP settings or therapy should be reviewed as your weight changes. Do not adjust or discontinue CPAP on your own.

Frequently asked questions

Is Ozempic or Wegovy approved for sleep apnea?
No. As of 2026, only tirzepatide (Zepbound) has an FDA approval specifically for obstructive sleep apnea in adults with obesity. Semaglutide products are not approved for this indication.

Does treating sleep apnea with tirzepatide replace CPAP?
This is a clinical decision. The trial showed meaningful improvements in apnea events, but whether to continue, adjust, or discontinue CPAP should be decided with your clinician and sleep specialist.

Can weight loss from any GLP-1 help sleep apnea?
Weight loss in general is associated with improvements in obstructive sleep apnea severity, because excess weight around the neck and chest contributes to airway obstruction. But individual outcomes vary and should be discussed with a clinician.

How do I know if I have moderate-to-severe sleep apnea?
Sleep apnea is diagnosed by a sleep study (polysomnography or home sleep test). Severity is measured by the apnea-hypopnea index — the number of breathing interruptions per hour. A clinician or sleep specialist arranges this.